What do systematic reviews say?

BBV152 – Bharat Biotech vs placebo

BBV152 – Bharat Biotech showed no clear difference in any adverse eventi compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1 [0.94, 1.07]
  1 study · 25753 participants
  High

BBV152 – Bharat Biotech vs placebo

BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.43, 0.97]
  1 study · 25928 participants
  High

BBV152 – Bharat Biotech vs placebo

BBV152 – Bharat Biotech showed no clear difference in local reactogenicity eventsg compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.95, 1.24]
  2 studies · 25750 participants
  High

NVX‐CoV2373 – Novavax vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NVX‐CoV2373 – Novavax vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 42175 participants
  Moderate

mRNA‐1273 – ModernaTX vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 31632 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25452 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.9 [0.3, 2.68]
  1 study · 29582 participants
  Low

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax leads to higher systemic reactogenicity eventsj compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.21 [1.17, 1.25]
  3 studies · 31063 participants
  High

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax probably leads to higher any adverse eventm compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.15 [1.05, 1.26]
  5 studies · 46231 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.92 [0.74, 1.14]
  4 studies · 38802 participants
  Low

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax leads to higher local reactogenicity eventsj compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 2.78 [1.99, 3.88]
  3 studies · 31063 participants
  High

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28674 participants
  Moderate

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

FINLAY‐FR‐2 – Instituto Finlay de Vacunas probably leads to lower all‐cause mortalitye compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.37 [0.17, 0.8]
  1 study · 28674 participants
  Moderate

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all-cause death compared with supragingival scaling (plus placebo) (very low certainty).

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes

  12 months
  Peto OR 7.48 [0.15, 376.98]
  1 study · 165 participants
  Very low

Autologous platelet‐rich plasma vs placebo or no treatment

It is very uncertain whether platelet rich plasma changes presence of dry socket compared with placebo or no treatment (very low certainty).

• Local interventions for the management of alveolar osteitis (dry socket) 2022 · Cochrane All outcomes

  Follow-up: median 7 days
  RR 0.51 [0.19, 1.33]
  2 studies · 127 participants
  Very low

Artemisia desertorum spreng (Yunnan) vs placebo

Artemisia desertorum spreng (Yunnan) showed no clear difference in presence of dry socket compared with placebo; GRADE not reported.

• Local interventions for the management of alveolar osteitis (dry socket) 2022 · Cochrane All outcomes

  Follow-up: median 7 days
  RR 0.28 [0.06, 1.28]
  1 study · 182 participants
  GRADE not reported

Antibiotic prophylaxis before dental procedure vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Antibiotic prophylaxis for preventing bacterial endocarditis following dental procedures 2022 · Cochrane All outcomes
  Adverse effects of antibiotics | No data reported | 248 (1 study) | - | -
  0 studies
  No studies found